MDR Investigator´s Brochure

Consolidating MDCG 2024-5 and ISO 14155 for Medical Devices

The MDR Investigator’s Brochure (IB) is a foundational document in clinical research for medical devices. Under the EU Medical Device Regulation (EU MDR) 2017/745, preparing an Investigator’s Brochure is a mandatory requirement for any clinical investigation. This document consolidates all relevant clinical and non‑clinical data about the investigational device and serves as the primary reference for investigators responsible for conducting MDR‑compliant clinical studies.

The purpose of the MDR Investigator’s Brochure is to ensure that every clinical investigation is supported by robust, transparent, and scientifically sound information. It provides investigators with the knowledge necessary to evaluate device performance, understand potential risks, and ensure patient safety throughout all study phases.

To meet MDR expectations, the IB must be developed in alignment with ISO 14155, the international standard governing Good Clinical Practice for medical device clinical investigations. ISO 14155 specifies how clinical studies must be designed, conducted, recorded, and reported, and the Investigator’s Brochure plays a central role in ensuring compliance with these principles.

In addition, MDCG 2024‑5 offers further guidance on the structure and content of the MDR Investigator’s Brochure. This MDCG document stresses clarity, completeness, and scientific rigor, ensuring the IB provides a comprehensive overview of the investigational device. It highlights the need for detailed information on device design, intended purpose, manufacturing, prior clinical experience, and risk–benefit considerations, elements essential for informed clinical oversight.

Beyond summarizing design and safety information, the MDR Investigator’s Brochure compiles clinical evidence from previous bench tests, preclinical studies, and human data (where available). This evidence synthesis supports ethical review, risk assessment, and regulatory submission, forming the backbone of a well‑prepared clinical investigations. plan. Ultimately, a high‑quality Investigator’s Brochure strengthens both regulatory compliance and patient protection, ensuring that investigational devices are evaluated responsibly and scientifically.

MDR investigator´s brochure: Regulatory Context and Importance

Regulated by EU MDR 2017/745

The European Union Medical Device Regulation (EU MDR) sets strict requirements for clinical investigations in the EU. Article 71.4 references the Investigator’s Brochure (IB) twice and clearly defines what it must contain.

According to this article, the IB must present comprehensive information about the investigational device. It should also reflect the current state of scientific knowledge. This ensures the device can demonstrate safety, performance, and clinical benefits during the investigation.

Article 71.4 explicitly requires a detailed description of the device. This includes its intended use, risk classification, design features, and manufacturing details. It must also include all necessary clinical and non‑clinical data available at the time of submission.

Together, these elements ensure the investigational device is properly assessed before and during clinical investigations. They also help investigators confirm that the device is used safely, consistently, and in line with MDR expectations.

Standardized by ISO 14155

ISO 14155 mentions the Investigator’s Brochure (IB) four times and sets the standard for good clinical practice in clinical investigations involving human subjects. It defines how studies must be designed, conducted, recorded, and reported.

In Section 6.5 and Annex B, ISO 14155 outlines the core requirements for the IB. It states that the IB must give principal investigators sufficient safety and performance data from pre‑clinical studies and previous clinical investigations. This information helps investigators understand the device and use it safely during the study.

Moreover, ISO 14155 requires that the IB remain continuously updated. As new, relevant information emerges during a clinical investigation, sponsors must revise the IB. This ensures the document stays accurate, current, and comprehensive throughout the study lifecycle.

Detailed in MDCG 2024-5

MDCG 2024‑5 provides detailed guidance on what the MDR Investigator’s Brochure must include to support a clinical investigation application. This document clarifies how sponsors should compile the IB so it fully meets regulatory expectations and facilitates an efficient review by competent authorities.

The guidance also stresses the importance of clear, balanced, and non‑promotional content. Using this approach ensures investigators receive reliable information and can make informed decisions about participating in the clinical investigation.

Structuring the MDR Investigator´s Brochure: A Detailed Approach

1. Device Description and Specifications

The detailed description of the investigational device forms a crucial part of the Investigator´s Brochure (IB). This section must provide a thorough overview of the device, including its design, operational mechanics, and the scientific rationale behind its development. The aim is to furnish investigators with the necessary information to understand the device’s functionality, potential clinical applications, and safety features.

General Information

• Device Identification: This includes the official name, model number, and any other identifiers unique to the device. It’s essential to maintain consistency in terminology throughout the IB to avoid confusion.
• Regulatory Status: Details about the device’s approval status, including whether it is under investigation or already approved for use in other contexts or regions. This should align with the regulatory requirements of the EU MDR and include any CE marking statuses.

Technical Details

• Design Overview: A comprehensive description of the device’s design, highlighting any innovative features. This should cover the underlying technology, operational principles, and any software components integral to the device’s function.
• Materials and Components: Detailed information about the materials used in the device’s construction, especially those in contact with patients. Information on biocompatibility must be included as per ISO 10993-1 standards, ensuring that all materials are safe for intended use scenarios.
• Manufacturing Process: Insight into the manufacturing processes, including quality control measures and compliance with current good manufacturing practices (cGMP). This transparency helps assure investigators of the device’s reliability and consistency in production.

Operational Mechanics

• Mechanism of Action: Explanation of how the device achieves its intended medical purpose. This includes a description of any mechanical, electronic, or biological actions that are central to the device’s operation.
• Instructions for Use: Clear, step-by-step instructions on how the device should be operated during the clinical investigations, including setup, usage, and shutdown procedures, if applicable. This section should also address any training requirements for investigators or clinical staff.

Safety Features

• Safety Mechanisms: Details of built-in safety features designed to protect the patient and user, such as automatic shut-offs, error alerts, and fail-safes.
• Known Risks and Mitigation Strategies: An overview of identified risks associated with the device, along with strategies implemented to mitigate these risks. This should be directly linked to the risk management processes detailed in a later section of the IB.

This section of the IB serves not only to inform but also to build confidence among clinical investigators and regulatory bodies regarding the investigational device’s suitability for clinical investigations. By providing a clear and detailed description of the device, the IB helps ensure that all stakeholders have a deep understanding of the device’s capabilities, safety, and potential impact on patient health.

2. Clinical and Non-Clinical Data

This section of the IB comprehensively details the investigational device’s performance in both pre-clinical and clinical settings. It should offer a thorough summary of all relevant studies, ensuring that investigators have access to comprehensive data that supports the safety and performance of the device.

Pre-Clinical Studies

• Overview of Studies: A summary of all pre-clinical studies conducted, including laboratory, in vitro, in vivo (animal studies), and any biomechanical or biochemical research relevant to the device’s intended use. This should include detailed results and interpretations.
• Safety and Performance Data: Detailed findings from pre-clinical tests that assess the safety and performance of the device. This includes any biocompatibility testing done in accordance with ISO 10993, mechanical and durability testing, and any other relevant safety evaluations.
• Regulatory Compliance: Explanation of how pre-clinical testing complies with relevant regulations and standards, including any deviations from standard protocols and justifications for such deviations.

Clinical Data

• Summary of Clinical Investigations: A detailed account of previous and ongoing clinical investigations involving the device, including study design, methodology, sample size, duration, endpoints, and primary outcomes. This should include both published and unpublished data.
• Safety and Performance Outcomes: Analysis of data related to the device’s safety and performance from clinical investigations, highlighting any significant adverse events, device deficiencies, and corrective actions taken.
• Comparative Analysis: If applicable, comparative data from similar devices or previous versions of the same device, providing a contextual understanding of the investigational device’s performance.

Integration of Data

• Data Correlation: Correlate pre-clinical findings with clinical outcomes to illustrate how earlier studies have informed clinical investigation designs and expectations.
• Rationale for Clinical Investigation: Based on the integrated data, provide a comprehensive rationale for proceeding with further clinical investigations, outlining expected benefits, potential risks, and overall clinical value of the device.

Justification of Clinical Relevance

• Scientific Literature: Review and summarize relevant scientific literature that supports the use, safety, and performance of the device. This should include any meta-analyses, systematic reviews, and key opinion papers.
• Regulatory Considerations: Discuss any regulatory feedback or advisories that have impacted the clinical development of the device, including any special designations or regulatory pathways that are being utilized.

This section of the IB is critical for establishing the scientific and clinical foundation upon which the clinical investigation is based. It must convincingly demonstrate that the investigational device has been thoroughly evaluated in non-clinical settings and that the data derived from these evaluations justify its examination in human subjects. By providing clear, comprehensive, and scientifically sound data, this section helps ensure that the clinical investigation proceeds with a well-defined understanding of the device’s potential impacts on patient safety and performance.

3. Risk Management

Overview of Risk Assessment

• Risk Identification: Detail all potential risks associated with the use of the device, derived from pre-clinical studies, historical data from similar devices, and initial clinical investigations. This should include both device-specific and procedure-related risks.
• Risk Analysis: Evaluate the likelihood and potential impact of identified risks. Use qualitative and quantitative methods to assess how these risks could affect patient safety and the reliability of study results.

Risk Control Strategies

• Risk Mitigation Measures: Outline specific strategies and actions taken to minimize identified risks. This includes design modifications, safety features integrated into the device, and specific procedural steps taken during clinical investigations to mitigate risks.
• Monitoring and Reporting: Procedures for ongoing monitoring of risks throughout the clinical investigation. Detail how adverse events and device deficiencies will be recorded, analyzed, and reported. Include information on the data monitoring committee’s role and any interim analyses planned.

Documentation and Communication of Risks

• Risk Communication Plan: Describe how information about risks is communicated to all stakeholders, including clinical investigation sites, investigators, and participants. Ensure that all parties are aware of potential risks and the measures in place to protect participants.
• Training Programs: Detail training provided to clinical staff and investigators to recognize, manage, and report risks effectively. Training should cover the proper use of the device, recognition of adverse events, and emergency procedures.

Benefit-Risk Analysis

• Overall Benefit-Risk Profile: Synthesize the benefits and risks of the device to demonstrate that the anticipated benefits outweigh the risks. This analysis should be based on data from pre-clinical and clinical studies and should be updated with new information obtained during the investigation.
• Regulatory Compliance: Ensure that the risk management approach complies with ISO 14971, the international standard for the application of risk management to medical devices, and any specific regulatory requirements pertinent to the device.

Continuous Risk Management

• Review and Update: Mechanisms for regularly reviewing and updating the risk management plan as new data become available or as circumstances change during the investigation. This includes planned revisions following interim analyses or in response to external factors such as newly published research or changes in clinical practice.

Risk Management Documentation

• Documentation Standards: Maintain comprehensive documentation of all risk management activities, including assessments, decisions made, actions taken, and the rationale behind each decision. Documentation should be readily accessible and auditable.

This section of the MDR Investigator´s Brochure is essential for ensuring that all potential and actual risks are adequately managed throughout the clinical investigation. The risk management  protects participants and also ensures the integrity of the clinical data and supports the ultimate goal of demonstrating the device’s safety and performance.

4. Regulatory and Compliance Information

Compliance with General Safety and Performance Requirements (GSPRs)

• GSPR Alignment: List and describe how the investigational device complies with each of the applicable General Safety and Performance Requirements as outlined in Annex I of the EU MDR. This includes detailing the device’s design, manufacturing processes, and performance characteristics that ensure compliance.
• Standards and Specifications: Identify all standards and Common Specifications (CS) applied during the device’s development and testing phases, such as ISO standards for medical devices, IEC standards for electrical devices, etc. Provide a justification for each standard’s application and describe how it contributes to the device’s compliance with the GSPRs.

Documentation of Compliance

• Evidence of Compliance: Provide documentation or summaries of test results and analyses that demonstrate the device’s compliance with the aforementioned standards and requirements. This should include both pre-clinical and clinical data, as well as any data related to device modifications.
• Notified Body Interaction: Detail interactions with Notified Bodies, including any conformity assessments or certifications obtained. This section should also cover the scope of the assessments, highlighting critical areas reviewed and any recommendations made by the Notified Body.

Regulatory Submissions and Approvals

• Regulatory Filings: List all regulatory filings made for the device, including submissions to national and international regulatory agencies. Detail the status of these filings, any approvals received, and pending decisions.
• Labeling and Instructions for Use: Ensure that the device’s labeling and instructions for use comply with regulatory requirements. Include information on language requirements, symbols used, and any specific labeling considerations for investigational use.

Compliance with International Guidelines

• ISO 14155 Compliance for Clinical Investigations: Demonstrate how the clinical investigations comply with ISO 14155, which outlines good clinical practice for the design, conduct, recording, and reporting of clinical investigations performed on human subjects. Discuss any deviations from these guidelines and provide justifications.
• Ethical Considerations: Address ethical considerations in compliance with the Declaration of Helsinki and local regulations where the clinical investigations are being conducted. Include information on ethical review board approvals, informed consent processes, and any other ethical safeguards in place.

Continuous Regulatory Monitoring

• Monitoring Changes in Regulations: Establish a process for monitoring and responding to changes in regulatory requirements that could affect the ongoing clinical investigations. This includes updates to laws, guidelines, or standards relevant to the device or its clinical investigation.
• Adaptation to Regulatory Changes: Describe the strategies for adapting the clinical investigation and documentation practices in response to regulatory changes. Ensuring ongoing compliance throughout the investigation’s duration.

This section of the MDR IB serves to assure all stakeholders. Including regulatory authorities, ethics committees, and clinical investigators, that the device meets all necessary safety, performance, and regulatory requirements for clinical investigation. It underscores the sponsor’s commitment to adhering to the highest standards of regulatory compliance and patient safety.

5. MDR Investigator´s Brochure Revisions and Updates

Update Procedures

• Scheduled Updates: Define a schedule for regular reviews and updates of the IB. These should be strategically timed to follow major study milestones, such as the completion of certain phases or after significant data analysis points.
• Trigger Events for Ad-Hoc Updates: Specify conditions or “trigger events” that necessitate immediate updates outside of the regular schedule. These may include significant adverse events, changes in regulatory requirements, or substantial amendments to the clinical investigation protocol.

Document Control and Version Management

• Version Tracking: Implement a version control system to track all changes made to the IB. Each version should be clearly numbered and dated, with a summary of changes provided in each new version.
• Archiving Procedures: Establish procedures for archiving superseded versions of the IB. This ensures that previous versions are accessible for reference or regulatory review, maintaining a complete history of document changes.

Communication of Updates

• Notification System: Develop a systematic approach for notifying all stakeholders, including clinical investigation sites, ethics committees, and regulatory authorities, of updates to the IB. Notifications should detail the nature of the updates and their implications for ongoing clinical activities.
• Training on Updates: Coordinate training sessions for all relevant clinical investigation personnel whenever significant updates are made to the IB. This ensures that all team members are informed about the latest device information, safety protocols, and compliance requirements.

Regulatory Compliance of Updates

• Regulatory Submission of Updated IB: Outline the procedures for submitting updated versions of the IB to regulatory authorities as required by local regulations or international guidelines. Include timelines for submissions following significant changes or discoveries during the investigation.
• Compliance Audits: Regularly audit the update and revision processes to ensure they comply with both internal quality standards and external regulatory requirements. Audits help identify and rectify any discrepancies or inefficiencies in the documentation process.

Feedback Mechanism

• Stakeholder Feedback: Establish a feedback mechanism allowing investigators and other stakeholders to provide input on the IB’s content and layout. This feedback can be instrumental in improving the clarity and utility of the document.
• Continuous Improvement: Use stakeholder feedback and audit outcomes to continually refine the update and revision processes. This ensures that the procedures remain effective and responsive to the needs of the clinical investigation and regulatory landscape.

This section ensures that the MDR IB remains a living document, reflective of the latest scientific knowledge and regulatory standards. By meticulously managing updates, ensuring comprehensive communication and training regarding these changes. Sponsors can maintain the document’s relevance and utility throughout the clinical investigation process.

In summary, the MDR Investigator´s Brochure must be actively managed to remain a current and compliant resource throughout the study. The processes outlined in this section provide a framework for achieving this, ensuring that the MDR IB continuously supports the safe and performance evaluation of the investigational device.

Key Insights

The Role of the MDR Investigator’s Brochure in Medical Device Research

The MDR Investigator’s Brochure is a central document in any clinical investigation for medical devices. Its purpose goes far beyond regulatory compliance. It equips investigators, ethics committees, and regulatory authorities with the information they need to understand the investigational device. With this shared knowledge base, stakeholders can make informed decisions that protect participants and ensure reliable, high‑quality clinical data.

A Dynamic and Evolving Document

The IB is not static. Instead, it must evolve throughout the clinical investigation. As new data, observations, or safety information emerge, sponsors must update the MDR Investigator’s Brochure accordingly. This continuous revision process ensures the document remains accurate, transparent, and aligned with current knowledge. It also reinforces trust among investigators, ethics committees, and regulators.

Integrating Multidisciplinary Expertise

Developing a robust MDR Investigator’s Brochure requires input from multiple disciplines. Engineering, clinical research, regulatory affairs, quality assurance, and risk management all contribute essential insights. This multidisciplinary collaboration ensures the IB is scientifically sound, comprehensive, and reflective of the latest advancements in both medical technology and clinical practice.

Commitment to Transparency and Investigator Education

The MDR Investigator’s Brochure also serves as a critical educational resource. It explains the device’s development history, intended purpose, mechanism of action, and supporting evidence. By presenting this information clearly and objectively, the IB promotes transparency and strengthens the trust of investigators, clinical staff, participants, and the wider public.

Future Considerations

As regulations and standards continue to evolve, the MDR Investigator’s Brochure must adapt. Future developments may include more accessible digital formats, interactive layouts, and harmonized content that supports multinational studies. Proactive updates will be essential as global regulatory expectations shift and clinical research models become more complex.

Conclusion

The MDR Investigator’s Brochure is more than a regulatory requirement—it is a vital tool that shapes the scientific, ethical, and operational quality of clinical investigations. A clear, current, and compliant IB helps sponsors streamline the investigation process, strengthens regulatory confidence, and ultimately supports the development of safe and high‑performing medical devices.

This article has outlined a structured and practical approach to building an Investigator’s Brochure that meets MDR expectations. By following these principles, sponsors can conduct clinical investigations with the highest standards of safety, performance, and data integrity.